Inhaler errors in the CRITIKAL study: type, frequency, and association with asthma outcomes DB Price, M Román-Rodríguez, RB McQueen, S Bosnic-Anticevich, ... The Journal of Allergy and Clinical Immunology: In Practice 5 (4), 1071-1081. e9, 2017 | 377 | 2017 |
Burden of multiple sclerosis on direct, indirect costs and quality of life: National US estimates JD Campbell, V Ghushchyan, RB McQueen, S Cahoon-Metzger, ... Multiple sclerosis and related disorders 3 (2), 227-236, 2014 | 155 | 2014 |
Understanding barriers to medication adherence in the hypertensive population by evaluating responses to a telephone survey KV Nair, DA Belletti, JJ Doyle, RR Allen, RB McQueen, JJ Saseen, ... Patient preference and adherence, 195-206, 2011 | 106 | 2011 |
Long-term survival and cost-effectiveness associated with axicabtagene ciloleucel vs chemotherapy for treatment of B-cell lymphoma MD Whittington, RB McQueen, DA Ollendorf, VM Kumar, RH Chapman, ... JAMA network open 2 (2), e190035-e190035, 2019 | 95 | 2019 |
Long-term survival and value of chimeric antigen receptor T-cell therapy for pediatric patients with relapsed or refractory leukemia MD Whittington, RB McQueen, DA Ollendorf, VM Kumar, RH Chapman, ... JAMA pediatrics 172 (12), 1161-1168, 2018 | 93 | 2018 |
Cost-effectiveness of biological asthma treatments: a systematic review and recommendations for future economic evaluations RB McQueen, DN Sheehan, MD Whittington, JFM van Boven, ... Pharmacoeconomics 36, 957-971, 2018 | 90 | 2018 |
Assessing the value of mepolizumab for severe eosinophilic asthma: a cost-effectiveness analysis MD Whittington, RB McQueen, DA Ollendorf, JA Tice, RH Chapman, ... Annals of Allergy, Asthma & Immunology 118 (2), 220-225, 2017 | 84 | 2017 |
Cost-effectiveness of continuous glucose monitoring and intensive insulin therapy for type 1 diabetes RB McQueen, SL Ellis, JD Campbell, KV Nair, PW Sullivan Cost effectiveness and resource allocation 9, 1-8, 2011 | 81 | 2011 |
Cost and cost-effectiveness of large-scale screening for type 1 diabetes in Colorado RB McQueen, C Geno Rasmussen, K Waugh, BI Frohnert, AK Steck, L Yu, ... Diabetes care 43 (7), 1496-1503, 2020 | 75 | 2020 |
On-and off-label utilization of dalbavancin and oritavancin for Gram-positive infections T Morrisette, MA Miller, BT Montague, GR Barber, RB McQueen, M Krsak Journal of Antimicrobial Chemotherapy 74 (8), 2405-2416, 2019 | 75 | 2019 |
Long-acting lipoglycopeptides:“lineless antibiotics” for serious infections in persons who use drugs T Morrisette, MA Miller, BT Montague, GR Barber, RB McQueen, M Krsak Open forum infectious diseases 6 (7), ofz274, 2019 | 63 | 2019 |
Economic burden of comorbid chronic kidney disease and diabetes RB McQueen, S Farahbakhshian, KF Bell, KV Nair, JJ Saseen Journal of medical economics 20 (6), 585-591, 2017 | 55 | 2017 |
Prognostic predictors relevant to end-of-life palliative care in Parkinson’s disease and related disorders: a systematic review U Akbar, RB McQueen, J Bemski, J Carter, ER Goy, J Kutner, MJ Johnson, ... Journal of Neurology, Neurosurgery & Psychiatry 92 (6), 629-636, 2021 | 42 | 2021 |
Economic differences in direct and indirect costs between people with epilepsy and without epilepsy AM Libby, V Ghushchyan, RB McQueen, JF Slejko, JL Bainbridge, ... Medical care 50 (11), 928-933, 2012 | 42 | 2012 |
The “e” in cost-effectiveness analyses. A case study of omalizumab efficacy and effectiveness for cost-effectiveness analysis evidence JD Campbell, RB McQueen, A Briggs Annals of the American Thoracic Society 11 (Supplement 2), S105-S111, 2014 | 37 | 2014 |
Cost-effectiveness uncertainty analysis methods: a comparison of one-way sensitivity, analysis of covariance, and expected value of partial perfect information JD Campbell, RB McQueen, AM Libby, DE Spackman, JJ Carlson, ... Medical Decision Making 35 (5), 596-607, 2015 | 29 | 2015 |
Alternative approaches to quality-adjusted life-year estimation within standard cost-effectiveness models: literature review, feasibility assessment, and impact evaluation JJ Carlson, ED Brouwer, E Kim, P Wright, RB McQueen Value in Health 23 (12), 1523-1533, 2020 | 27 | 2020 |
Incremental increases in economic burden parallels cardiometabolic risk factors in the US RB McQueen, V Ghushchyan, T Olufade, JJ Sheehan, KV Nair, JJ Saseen Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 233-241, 2016 | 27 | 2016 |
An evaluation of the impact of patient cost sharing for antihypertensive medications on adherence, medication and health care utilization, and expenditures JA Pesa, J Van Den Bos, T Gray, C Hartsig, RB McQueen, JJ Saseen, ... Patient preference and adherence, 63-72, 2012 | 25 | 2012 |
Valuing chimeric antigen receptor T-cell therapy: current evidence, uncertainties, and payment implications MD Whittington, RB McQueen, JD Campbell Journal of Clinical Oncology 38 (4), 359-366, 2020 | 24 | 2020 |